A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) (NCT06643481)
A Phase 2, Randomized, Double-blind, Placebo-controlled Parallel Group Study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) Over 40 Weeks Followed by an Open Label Extension (ASTRALS)
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE).
Who can join: Review the eligibility criteria below.
Location: University of California San Diego — La Jolla, California
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (74 Sites)
Showing the first 25 of 74 sites.
- University of California San Diego — La Jolla, California
- Loma Linda University Health — Loma Linda, California
- Keck Medical Center USC — Los Angeles, California
- UC San Francisco Medical Center — San Francisco, California
- University of Miami — Miami, Florida
- Orlando Health Clinical Trials — Orlando, Florida
- Emory University School of Medicine — Atlanta, Georgia
- University Of Kansas Medical Center — Kansas City, Kansas
- Massachusetts General Hospital — Boston, Massachusetts
- University of Nebraska Medical Center — Omaha, Nebraska
- Lange Neurology PC — New York, New York
- University of Rochester Medical Center — Rochester, New York
- Atrium Health — Charlotte, North Carolina
- Duke University Health System — Durham, North Carolina
- Univ of Cincinnati Medical Center — Cincinnati, Ohio
- The Ohio State University — Columbus, Ohio
- Temple University — Philadelphia, Pennsylvania
- AMR Knoxville — Knoxville, Tennessee
- Austin Neuromuscular Center — Austin, Texas
- Nerve and Muscle Center of Texas — Houston, Texas
- University of Washington Medical Center — Seattle, Washington
- Novartis Investigative Site — North Ryde, New South Wales
- Novartis Investigative Site — Herston, Queensland
- Novartis Investigative Site — Caulfield South, Victoria
- Novartis Investigative Site — Southport,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Amyotrophic Lateral Sclerosis (ALS)
- HEALEY ALS Platform Trial - Regimen I NUZ-001 — Boston, Massachusetts
- Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY) — Phoenix, Arizona
- Resiliency Intervention for Patients With ALS and Their Care-Partners — Boston, Massachusetts
- Safety Study of XT-150 in Participants With ALS — Phoenix, Arizona
- A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS — Boston, Massachusetts
Explore by condition: All Amyotrophic Lateral Sclerosis (ALS) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.